MedTrace Logo

European Study in Bone Sarcoma Patients Over 40 Years

NCT02986503 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-12-08

No results posted yet for this study

Summary

The study is a first step of a process to establish the standard chemotherapy treatment with the aim to improve outcome for patients with these rare tumours. For this reason the study will be non-controlled clinical trial.

In this regard, the study aims to determine the feasibility of intensive chemotherapy in this age group, and/or separate efficacy analyses according to the different histologic categories and whether the number of patients recruited by the co-operating groups permits future randomised studies.

Conditions

Interventions

DRUG

Doxorubicin+cisplatin+ifosfamide

Chemotherapy for Good responder high grade osteosarcoma

DRUG

Doxorubicin+cisplatin+ifosfamide+methotrexate

Chemotherapy for Poor responder high grade osteosarcoma

Sponsors & Collaborators

  • Scandinavian Sarcoma Group

    collaborator OTHER

  • Cooperative Osteosarcoma Study Group

    collaborator UNKNOWN

  • Italian Sarcoma Group

    lead NETWORK

Principal Investigators

  • Stefano Ferrari, MD · Italian Sarcoma Group

Eligibility

Min Age
41 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2015-12-31
Completion
2016-11-30

Countries

  • Germany
  • Italy
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02986503 on ClinicalTrials.gov